Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06546488 · ClinicalTrials.gov registry record
Cognitive Assessment Tools for Huntington's Disease.
A clinical trial of Huntington Disease, sponsored by Ohio State University.
- Recruiting
- Registry status
- 76
- Enrollment target
- 1
- Study location
NCT06546488: Recruiting study of Huntington Disease, sponsored by Ohio State University.
NCT06546488 is a study of Huntington Disease that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 76 participants, below the 633-participant average among 35 other Huntington Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06546488, a study of Huntington Disease, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.
Primary Outcome
Comparison of scores on Symbol Digit Modality Test (SDMT) and Coding Test. Associations will be investigated using Spearman correlations.
Conditions Studied
Interventions
- BEHAVIORAL Assessments
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2027-12-01 |
What NCT06546488 shows while recruiting
NCT06546488 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 633-participant average among 35 other Huntington Disease trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which Assessments is the first listed.
NCT06546488 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06546488 about?
NCT06546488 is a clinical study titled "Cognitive Assessment Tools for Huntington's Disease.". The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is...
What is the current status of trial NCT06546488?
This trial is currently recruiting. The enrollment target is 76 participants. The study started on 2025-06-20. Estimated completion is 2027-12-01.
What conditions does trial NCT06546488 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT06546488?
The interventions under investigation include: Assessments (BEHAVIORAL).
Who is sponsoring clinical trial NCT06546488?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06546488 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06546488's enrollment target sits among peer trials
76 22nd of 35 higher than 14 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI